Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2014 Financial Results on July 31, 2014

  Seattle Genetics to Host Conference Call and Webcast Discussion of Second
  Quarter 2014 Financial Results on July 31, 2014

Business Wire

BOTHELL, Wash. -- July 9, 2014

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it will report its
second quarter 2014 financial results on Thursday, July 31, 2014, after the
close of financial markets. Following the announcement, company management
will host a conference call and webcast discussion of the results and provide
a general corporate update. Access to the event can be obtained as follows:

LIVE access on Thursday, July 31, 2014

1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

  *Telephone 800-839-7875 (domestic) or 913-312-0979 (international);
    conference ID 7088135
  *Webcast available at www.seattlegenetics.com/ in the Investors and News
    section

REPLAY access

  *Telephone replay will be available beginning at approximately 4:30 p.m. PT
    on Thursday, July 31, 2014 through 10:00 p.m. PT on Monday, August 4, 2014
    by calling 888-203-1112 (domestic) or 719-457-0820 (international);
    conference ID 7088135
  *Webcast replay will be available on the Seattle Genetics website at
    www.seattlegenetics.com/ in the Investors and News section

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and
commercialization of innovative antibody-based therapies for the treatment of
cancer. Seattle Genetics is leading the field in developing antibody-drug
conjugates (ADCs), a technology designed to harness the targeting ability of
antibodies to deliver cell-killing agents directly to cancer cells. The
company’s lead product, ADCETRIS^® (brentuximab vedotin), is an ADC that, in
collaboration with Takeda Pharmaceutical Company Limited, is commercially
available for two indications in more than 40 countries, including the U.S.,
Canada, Japan and members of the European Union. Additionally, ADCETRIS is
being evaluated broadly in more than 30 ongoing clinical trials. Seattle
Genetics is also advancing a robust pipeline of clinical-stage ADC programs,
including SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME and ASG-15ME. Seattle
Genetics has collaborations for its ADC technology with a number of leading
biotechnology and pharmaceutical companies, including AbbVie, Agensys (an
affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More
information can be found at www.seattlegenetics.com.

Contact:

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com
 
Press spacebar to pause and continue. Press esc to stop.